Editorial: Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness
- PMID: 36641603
- DOI: 10.14283/jpad.2022.103
Editorial: Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness
Conflict of interest statement
JC has provided consultation to Acadia, Actinogen, Alkahest, AlphaCognition, AriBio, Biogen, BioVie, Cassava, Cerecin, Corium, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, GAP Innovations, Grifols, Janssen, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Sage Therapeutics, Signant Health, Simcere, Sunbird Bio, Suven, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. JC is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053; NIA grant P30AG072959; NIA grant R35AG71476; Alzheimer’s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and the Joy Chambers-Grundy Endowment.
Comment on
-
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102. J Prev Alzheimers Dis. 2023. PMID: 36641605 Clinical Trial.